• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 3. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 4. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 5. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines Pyrrolopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines

Comprehensive Overview of 7-Bromo-3-chloro-1H-pyrrolo[2,3-c]pyridine (CAS No. 1190309-88-6)

7-Bromo-3-chloro-1H-pyrrolo[2,3-c]pyridine (CAS 1190309-88-6) is a heterocyclic organic compound that has garnered significant attention in pharmaceutical and agrochemical research due to its unique structural properties. This brominated and chlorinated derivative of the pyrrolopyridine scaffold is widely utilized as a key intermediate in the synthesis of bioactive molecules. Its molecular formula, C₇H₄BrClN₂, highlights the presence of halogen atoms, which are critical for modulating electronic and steric effects in drug design.

In recent years, the demand for 7-Bromo-3-chloro-1H-pyrrolo[2,3-c]pyridine has surged, particularly in the development of kinase inhibitors and antiviral agents. Researchers are increasingly exploring its potential in targeting protein-protein interactions (PPIs) and allosteric binding sites, which are hot topics in modern drug discovery. The compound's pyrrolopyridine core is structurally analogous to purine bases, making it a versatile building block for nucleoside mimetics and small-molecule therapeutics.

One of the most frequently searched questions related to this compound is: "What are the applications of 7-Bromo-3-chloro-1H-pyrrolo[2,3-c]pyridine in medicinal chemistry?" The answer lies in its ability to serve as a precursor for JAK-STAT inhibitors, BTK inhibitors, and other targeted therapies. Its halogen substituents enhance binding affinity and metabolic stability, addressing common challenges in lead optimization. Additionally, its heteroaromatic system enables π-stacking interactions, a feature highly valued in fragment-based drug discovery.

From a synthetic chemistry perspective, CAS 1190309-88-6 is often discussed in forums focusing on cross-coupling reactions such as Suzuki-Miyaura and Buchwald-Hartwig couplings. These methods are pivotal for introducing diverse functional groups to the pyrrolopyridine framework, enabling the creation of libraries for high-throughput screening (HTS). The compound's compatibility with microwave-assisted synthesis further aligns with the industry's shift toward green chemistry and process intensification.

Another trending topic is the role of 7-Bromo-3-chloro-1H-pyrrolo[2,3-c]pyridine in cancer immunotherapy. Recent studies suggest its derivatives may modulate immune checkpoints, a breakthrough area in oncology research. This aligns with Google Trends data showing rising searches for "halogenated heterocycles in immunotherapy" and "small molecules for immune modulation". The compound's dual halogenation offers a strategic advantage in tuning lipophilicity and cell permeability, critical factors for blood-brain barrier penetration.

Quality control of 7-Bromo-3-chloro-1H-pyrrolo[2,3-c]pyridine is another area of interest, with analytical techniques like HPLC-MS and NMR spectroscopy being essential for verifying purity. Suppliers often highlight ≥98% purity as a benchmark, addressing concerns about byproduct formation during halogenation steps. The compound's stability under ambient storage conditions makes it a practical choice for industrial-scale applications.

In conclusion, CAS 1190309-88-6 represents a multifaceted tool for researchers exploring structure-activity relationships (SAR) in drug development. Its relevance to precision medicine and computational chemistry ensures sustained demand, while ongoing studies continue to uncover novel applications in neurodegenerative disease and infectious disease research. As synthetic methodologies evolve, this compound will likely remain a cornerstone in the design of next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)